Professor Jonathan Emberson
BA, MSc, PhD
Professor of Medical Statistics and Epidemiology
- MRC Population Health Research Unit Programme Leader
- MSc in Global Health Science Module Lead: Clinical Trials and Meta-Analysis
Jonathan is Professor of Medical Statistics and Epidemiology within the Nuffield Department of Population Health. After graduating in Mathematics in 1998, he studied statistics and epidemiology at MSc and PhD level before joining the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2004.
His main research involves studying the causes and prevention of cardiovascular diseases through the design, conduct and analysis of large-scale observational cohort studies, randomised controlled trials, and individual-participant-data meta-analyses of both types of study. He is the UK Principal Investigator and MRC Population Health Research Unit (MRC-PHRU) Programme Leader for the Mexico City Prospective Study, a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Independent relevance of adiposity measures to coronary heart disease risk among 0.5 million adults in UK Biobank.
Trichia E. et al, (2023), Int J Epidemiol
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Wijesurendra RS. et al, (2023), Eur Heart J
Genotyping, sequencing and analysis of 140,000 adults from Mexico City.
Ziyatdinov A. et al, (2023), Nature, 622, 784 - 793